[Video]

 Wei Yuquan

Academician of the Chinese Academy of Sciences (CAS), Director of the Cancer Center of West China Hospital and the State Key Laboratory of Biotherapy, President of China Medicinal Biotech Association (CMBA), and President of SCIMEA.

On November 10, the 2019 China-Japan Advanced Medical and New Drug R&D Summit and Achievements Transformation Conference was held in Chengdu. Co-organized by the Sichuan International Medical Exchange and Promotion Association (SCIMEA) and the Translational Research Center for Medical Innovation (TRI), the conference showcased nearly 1,000 China’s and Japan’s state-of-the-art medical technology, new drug research and development achievements and products for transformation and investment, including over 400 Japan’s products of regenerative medicine, immunotherapy, and gene therapy, such as stem cell therapy and biomaterials that are from ongoing and completed clinical trials.

According to Mr. Wei, Chairman of the conference, the conference officially launched the China-Japan biomedical achievement transformation platform. While bringing together advanced medical achievement from China and Japan and realizing precision supply, the platform overcomes barriers to communication, improves the efficiency of achievement transformation, promotes interaction between the industry and capital, shares policy-based dividends, and expands industrial clusters. He believed that it enjoyed the strengths of resources with a bright future ahead.

The conference bore witness to more than ten Chinese and Japanese companies' pharmaceutical research and development achievement transformation agreements signed on site. China and Japan will carry out in-depth cooperation in pharmaceutical research to jointly promote the transformation and upgrading of Sichuan and Chengdu pharmaceutical industries and the transformation of advanced medical technology and new drug R&D.

Source: The Cover

© SCIEMA and The Cover